Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The hematopoietic progenitor cells of patients with polycythemia vera (PV) or essential thrombocythemia (ET) are characterized by hypersensitivity to hematopoietic growth factors and formation of endogenous erythroid colonies. Recently, 4 groups reported almost simultaneously Janus kinase 2 (JAK2) V617F mutation in more than 80% of PV patients, 30% of patients with ET and in about 50% of patients with idiopathic myelofibrosis. The identification of the JAK2 mutation represents a major advance in the understanding of the molecular pathogenesis of MPDs that will likely permit a new classification and the development of novel therapeutic strategies for these diseases.
Hsu
Hui-Chi
HC
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, and Institute of Physiology, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. hchsu@vghtpe.gov.tw
D002908:Chronic Disease; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000209:etiology* / Q000235:genetics; D011087:Polycythemia Vera / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000235:genetics / Q000628:therapy
C507924:JAK2 protein, human; D053614:Janus Kinase 2